Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.
    Difference
    1%
    Check dated 2025-07-04T01:21:08.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    1%
    Check dated 2025-06-19T18:14:29.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T08:06:01.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T05:43:51.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:51:25.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    The webpage has undergone significant content changes, including the removal of detailed information about pembrolizumab, a key treatment for non-small cell lung cancer, and the addition of a new study identifier and version revision. The core content related to treatment protocols and eligibility criteria has been largely deleted.
    Difference
    44%
    Check dated 2025-04-16T01:48:33.000Z thumbnail image

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.